Board of Directors

mcneil_150

Robert McNeil

Chairman

Robert McNeil has over 35 years of experience as an active investor and management participant in seed and early-stage life science companies. He founded Sanderling Ventures in 1979 and has served since then as managing director of Sanderling’s seven investment partnerships.

Previously, Dr. McNeil was the seed investor for several companies that became the corner stones in the practice of modern medicine, including Advanced Cardiovascular Systems (the basis of Guidant Corp.) and Ventritex (the basis of rhythm management at St. Jude Medical). His ability to develop a close relationship with management and careful understanding of the companies’ technologies has allowed successful development of products at very early stage.

Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics from the University of California, Irvine.

guyett

Jane Guyett

Director

Jane Guyett, serves as a director at DalCor, and is also Chair of Connect Plus (M25) Ltd, the government’s largest road PFI transaction. Additionally, Jane is the senior non-executive director of UK Government Investments, managing the UK government’s corporate finance and divestment activities, and a non-executive director of UK Financial Investments, managing HM Treasury’s shareholdings in Royal Bank of Scotland, Lloyds Banking Group and UK Asset Resolution. Jane spent 15 years with Bank of America Merrill Lynch where she held various roles in London and New York.

She was chief operating officer (EMEA and Asia) of the Global Markets Group and sat on the Board of Bank of America Securities. Following her role at Bank of America Merrill Lynch, Ms. Guyett joined Kerry London Limited and Trade Direct Insurance Services as a non-executive director, positions she has held since 2011.

She began her career in Corporate Restructuring at Mitsubishi Bank Ltd London, before joining Bank of America in 1994. Jane Guyett holds a degree in economics.

henry_crop

Henry d’Abo

Director

Henry d’Abo is an experienced bio-tech investor, who has been involved in a number of different Cambridge based start-up companies.

Mr. d’Abo serves a director at DalCor and runs his own investment portfolio and has extensive property and agricultural interests in the UK and Germany.

Previously, he owned a controlling interest in a US based CRO which was sold in 2000.

Domitille de Vienne

Domitille de Vienne

Director

Domitille de Vienne has 10 years of experience in investment banking and private equity with a strong focus on healthcare companies. She serves as a director at DalCor and is an Analyst Principal at CDPQ’s global Private Equity group. She is based in London.

Before joining CDPQ, she served as an investment professional at Summit Partners in their European healthcare team, and has also worked for Citi in investment banking in London.

Domitille majored in finance and graduated from the ESCP Europe Business School in Paris, France.

rody

Rody Yared

Director

Rody Yared is an accomplished investment banker with over 17 years of experience spanning North America and the Middle East.

Rody serves as a director at DalCor, and is a managing director of Trussbridge.

Prior to Trussbridge, Mr. Yared was responsible for growing J.P.Morgan’s investment banking business in Abu Dhabi from 2010 to 2014. He also managed J.P.Morgan’s equity capital markets business in the MENA region, and was one of the founding members that established the bank’s investment banking franchise in the region in 2007. Previously, Mr. Yared served as head of the Syndicate & Equity Capital Markets department at SHUAA Capital in Dubai, after spending six years at Credit Suisse in New York.

He studied finance at Concordia University.